Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (...

Date 26 September 2015
Event European Cancer Congress 2015
Session Breast Cancer - Advanced Disease
Topics Breast Cancer, Metastatic
Presenter Brodowicz, T.